Lumexa Imaging Holdings stock
LMRINASDAQLumexa Imaging Holdings, Inc., HealthcareISIN US5502491062
47Score 47 out of 100, Weak
Price and trend
77 / 100
Price history
−19% since 2025The chart shows daily closing prices since 11 Dec 2025, adjusted for stock splits and excluding dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 35% above it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 74).
The price is 19% below its 52-week high. Largest decline since 11 Dec 2025: 63% (December 2025 to May 2026).
Chart figures for advanced users
- SMA 50$11.39
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$11.05
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)74
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.77
- The lowest closing price of the last twelve months.
- Resistance$18.53
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Lumexa Imaging Holdings, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $1.44B, is number 48 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.02B (up 7.8% year on year) and a loss of $47.1M.
- For fiscal 2026, analysts expect on average revenue of $1.07B (up 4.3%) and adjusted earnings per share of $0.64.
Show more
- MEQIRI Score 47 out of 100 (Weak): rank 428 of 714 in Healthcare, median 53.
- Our model puts fair value at $22.03, with the price 28% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 28% a year through 2028 (estimates from 6 analysts).Growth 50
Weaknesses
- Interest barely coveredOperating profit covers interest only 0.7 times.Stability 32
- Loss-makingLoss of $17.05M over the last 12 months.Fundamentals 27
- Volatile share priceVolatility 78% a year over the last 12 months.Stability 32
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
Modestly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $14.68 and expensive above $44.05 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 10.4%. At 11.4% the fair value would be $19.44, at 9.4% it would be $25.52.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 5.3% on the twelve months before. Revenue has grown solidly since 2023, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 11%, operating 3%, net −5%.
Debt & balance sheet
Fiscal 2025Debt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Mar 2027in 133 days
- Last reported
- 10 Nov 2026EPS reported $0.26 (expected $0.18)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.640.0%
- Revenue
- $1.07B0.0%
- Earnings per share
- $0.830.0%
- Revenue
- $1.12B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +4.6%Revenue and EPS guidance reiterated, adjusted EBITDA range narrowed to $235 million to $241 million with the midpoint unchanged at $238 million.
“And so with half the year complete, we're narrowing our adjusted EBITDA guidance range to $235 million to $241 million versus the previous range of $234 million to $242 million, while maintaining the midpoint at $238 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 12 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $476,863 in total.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Lumexa Imaging Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Embla Medical hf.EMBLA.CO $1.78B67
- EnovisENOV $1.65B45
- Medartis HoldingMED.SW $1.64B54
- VitrolifeVITR.ST $1.58B51
- CONMEDCNMD $1.51B69
- EL.En.ELN.MI $1.48B75
- NovocureNVCR $1.4B30
- PROCEPT BioRoboticsPRCT $1.34B41
ETFs that hold Lumexa Imaging Holdings
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.